Derms on Drugs

EADV serves up better croissants—and a packed menu of new mechanisms. The Derms dig into injectable RNA for BCC, a possible anti-scarring angle in HS, a TYK2 showdown, and an alopecia treatment that may keep working after treatment ends.

Dr. Jason Hawkes makes the case for putting speed first when choosing an advanced treatment for CSU. Remibrutinib works fast—but can he convince the Derms that fast is reason enough to put it first?

The Derms size up high-dose vitamin D, a head-to-head lichen planus trial, and whether contact dermatitis testing is overcalling the culprit.

The Derms question treatment monogamy: a personalized melanoma vaccine joins forces with immunotherapy, while dual therapy takes on refractory HS and AD.

In Utah, AI is getting its hands on the prescription pad—starting with topical acne treatment. The Derms grill Nolla’s CEO on the big questions: Who catches the misses, and is this better access or the beginning of the robot takeover?

Dr. Steve Daveluy makes the case that Cosentyx is the “just right” first biologic for HS—but not every Derm is ready to move past TNFs. Durability, infection risk, IBD, and insurance all enter the argument.

Exosomes may be real science, but the marketing has sprinted miles ahead of the data. The Derms dig into their promise for burns and epidermolysis bullosa—and why that pricey cosmetic vial may not contain what it claims.

Three papers, three practical questions: Who really needs antibiotics before derm surgery? What comes after an AD drug fails? And does taking oral minoxidil in the morning actually grow more hair—or just raise more eyebrows?

Dr. Marc Serota makes the case for targeted lab testing in CSU—but the Derms worry it may open a can of worms. The Chronic Urticaria Index gets a closer look, shotgun allergy panels get nowhere—but does he convince the Derms?

After 70,000 virtual consults, Dr. Joe English knows what a photo can—and can’t—tell you. He joins the Derms to talk diagnostic curveballs, hospital saves, and bringing dermatology where there’s no dermatologist in sight.